Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy
Open Access
- 8 July 2025
- journal article
- Published by Springer Nature in Breast Cancer Research
- Vol. 27 (1) , 127
Abstract
Managing Ductal Carcinoma in Situ (DCIS) remains challenging due to the lack of reliable biomarkers to predict radiotherapy (RT) response, leading to both overtreatment of indolent disease and undertreatment of aggressive cases. Through whole-exome sequencing of 147 DCIS cases, we characterized the genomic landscape of pure DCIS and identified genetic alterations associated with the risk of recurrence, either in-situ or invasive. DCIS lesions harbored frequent mutations in established cancer drivers (PIK3CA, TP53) and genes regulating tissue architecture, which likely enhanced pre-invasive cell fitness but lacked prognostic value. A subset of younger patients exhibited distinct mutational processes characterized by high mutational burden, though these were not linked to recurrence risk. Across the cohort, five mostly mutually exclusive genes (SH2B2, PDZD8, MYO7A, MUCL3, DNASE2B), involved in cell adhesion, membrane organization, and DNA degradation, were significantly associated with 10-year risk of local recurrence. In RT-treated patients, we identified 27 additional mutated genes uniquely associated with recurrence, along with SH2B2 and MUCL3. Most of these genes were involved in cytoskeletal regulation, cell adhesion, and cell-environment interactions. Mutations in metabolic regulators (MGAM2 and AADACL3) and REV1, which mediates DNA damage tolerance, may impair cellular responses to RT-induced stress. Notably, we identified distinct genes prognostic for in-situ versus invasive recurrence: nineteen genes predominantly involved in tissue structural maintenance in in-situ relapse, and thirteen genes primarily affecting cell-cycle and genome-stability pathways in invasive progression. Copy number analyses revealed that pure DCIS exhibits molecular subtype-specific patterns characteristic of invasive disease, with novel alterations associated with recurrence, including three non-adjacent gains and five losses in regions harboring oncogenes, tumor suppressor genes, and genes regulating structural integrity, cell-cell adhesion and interactions. While TP53, PIK3CA, and recurrent copy number alterations represent early events in tumorigenesis, they lack prognostic value in pure DCIS, underscoring the need for alternative biomarkers. Our findings identify key genetic alterations associated with local recurrence and RT resistance. We further uncovered distinct molecular programs underlying in-situ versus invasive recurrence, with mutations affecting tissue structural maintenance in in-situ relapse and cell-cycle/genome-stability pathways in invasive progression.Keywords
All Related Versions
Funding Information
- Breast Cancer Canada
- Ontario Graduate Scholarships
- Canadian Institute for Health Research (#391682, #391682, #391682, #391682, #391682, #391682, #391682, #391682)
- Canadian Foundation for Innovation J. Evans Leaders Fund grant (#43481, #43481)
This publication has 84 references indexed in Scilit:
- Early Dysregulation of Cell Adhesion and Extracellular Matrix Pathways in Breast Cancer ProgressionThe American Journal of Pathology, 2009
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic SubtypesJournal of Clinical Oncology, 2009
- MITOSTATIN, a putative tumor suppressor on chromosome 12q24.1, is downregulated in human bladder and breast cancerOncogene, 2008
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancerBreast Cancer Research and Treatment, 2007
- Oncogenic PI3K deregulates transcription and translationNature Reviews Cancer, 2005
- Cyclin D1, EMS1 and 11q13 Amplification in Breast CancerBreast Cancer Research and Treatment, 2003
- Allelic loss on chromosome band 18p11.3 occurs early and reveals heterogeneity in breast cancer progressionBreast Cancer Research, 2001
- PFM1 (PRDM4), a New Member of the PR-Domain Family, Maps to a Tumor Suppressor Locus on Human Chromosome 12q23–q24.1Genomics, 1999
- Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas.1992